News for ResMed Inc. (RSMDF)

U.S. stocks were higher, with the Nasdaq Composite gaining around 300 points on Thursday. Shares of Texas Instruments Incorporated TXN rose sharply during Thur...

Mizuho analyst Anthony Petrone has revised the price target for ResMed (RMD), lowering it from $280 to $265 while maintaining an Outperform rating. This adjustm

Citi has introduced a "downside 90-day catalyst watch" on ResMed Inc. (RMD), despite maintaining a Buy rating and setting a price target of A$44. The move comes

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 as of April 2nd. RMD’s trailing and forward P/E were 26.33 and 21.79 respectively according to Yahoo Finance. ResMed (RMD), a $32.5 billion […]

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc.

ResMed Inc (RMD), a leader in health technology, has announced that it will release its financial and operational results for the third quarter of fiscal year 2

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are going to take a look at where Resmed Inc.

**media[579431]**

ResMed Inc (RMD), a global leader in health technology, announced on March 19, 2025, the publication of a comprehensive meta-analysis in The Lancet Respiratory

**media[569550]**

Shares of ResMed Inc (RMD) surged 4.49% in mid-day trading on Mar 10. The stock reached an intraday high of $243.37, before settling at $242.88, up from its

On March 5, 2025, Peter Farrell, Director at ResMed Inc (RMD), sold 2,000 shares of the company, according to a SEC Filing. Following this transaction, the insi

ResMed Inc (RMD), a leader in health technology focused on sleep and respiratory care, released its fifth annual Global Sleep Survey on February 26, 2025. The s

PR NewswireWARSAW, Ind., Feb. 25, 2025 WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical techn

**media[537346]**

ResMed Inc (RMD) showcases robust revenue growth with a 10% increase in net revenue year-over-year.Significant improvement in gross margin and diluted earnings

Shares of ResMed Inc (RMD) fell 6.80% in mid-day trading on Jan 31. The stock reached an intraday low of $235.00, before recovering slightly to $240.13, dow

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode.